Thus, although our studies indicate that TP53 wild type AML are typically sensitive to the MDM2i/BETi combination, the dominant mechanisms underlying synergistic toxicity are likely to vary, especially given the genetic heterogeneity of AML2,3. This evidence concerns the gene RUNX3 and acute myeloid leukemia.